The study found that exisulind significantly suppressed the rise in PSA levels compared to placebo, especially in high-risk patients. Exisulind therapy also lengthened the median PSA doubling time, suggesting a delay in disease progression.
Two pivotal trials of Zevalin radioimmunotherapy show overall response rates of 80% and 74%, with patients achieving complete responses to therapy. Toxicity was primarily hematologic, transient and reversible.
The phase III clinical trial demonstrated a significant reduction in S. aureus bacteremias during the first ten months, but not after one-year follow-up. The study found that StaphVAX-induced antibodies protected against bloodstream infections.
Researchers identified SAANDS compounds as a potential new drug target for inducing apoptosis in abnormal cells. The compounds inhibit cGMP phosphodiesterases, triggering programmed cell death in cancerous and precancerous cells.
Familial adenomatous polyposis (FAP) patients treated with Aptosyn experienced a clinically significant reduction in precancerous colon polyp formation after six months of therapy. Over 18 months, patients showed an overall 75% reduction in polyps, highlighting the compound's potential as a treatment for FAP.
DoubleTwist has completed the first annotation of the human genome, revealing genes and valuable information. The analysis used Sun Enterprise supercomputers and DoubleTwist's proprietary genomic analysis software to process all available sequence data.
Researchers created a transgenic rat model with human CETP to study atherosclerosis. The study showed that elevated CETP contributes to the development of atherosclerosis, supporting the use of an antibody-based vaccine to raise HDL cholesterol levels.
The AVANT rotavirus vaccine demonstrated nearly 90% efficacy in preventing rotavirus disease in infants, surpassing existing vaccines' 49-68% efficacy rates. The vaccine was also found to be safe and immunogenic, with minimal side effects reported.
Researchers have genetically modified Salmonella bacteria to reduce virulence and increase safety while retaining tumor-targeting properties. The modified bacteria exhibit reduced ability to induce TNF-alpha and cause septic shock, making them safer for human use.
Dynavax's proprietary ISS-DNA alters immune response in allergic asthma, inhibiting symptoms and modifying inflammation. The company believes ISS-DNA therapy may provide a novel treatment for chronic allergic pulmonary inflammation.
In a Phase II study combining ONYX-015 with standard chemotherapy, nine out of ten patients experienced tumor regressions greater than 50 percent, including two complete responses. Thirty percent of patients treated with ONYX-015 alone showed significant tumor regression.
A combination of urine and blood-based tests has been found to be more sensitive in detecting HIV-1 antibodies, potentially identifying individuals with compartmentalized infections or immune responses. This breakthrough could lead to the development of a safe and effective AIDS vaccine.
Researchers successfully delivered genes encoding dopamine-producing enzymes into the brains of rats with induced Parkinson's disease, significantly reducing abnormal rotational movement. The treatment showed greater improvement when both genes were used together.